A RaPID Macrocyclic Peptide Inhibitor of ROR1/2 Strongly Reduces Proliferation of Diffuse Intrinsic Pontine Glioma Cells

Authors:
Publisher website
Google Scholar
Abstract
We report the de novo discovery of a cyclic peptide inhibitor of ROR1/2 from the RaPID (random nonstandard peptides integrated discovery) system. Multiple independent affinity selection campaigns converged on a highly conserved family of sequences exhibiting single-digit nanomolar binding affinities to ROR1. One peptide from this family containing three nonproteinogenic residues, including a key cyclic β-amino acid, displayed pronounced activity in cellular assays. Strikingly, this peptide induced potent growth inhibition across multiple Diffuse Intrinsic Pontine Glioma (DIPG) cell lines, whereas other family members had no measurable cellular effects. Mechanistic analysis revealed that the active peptide uniquely competes with Wnt5a, the endogenous ligand of ROR1, for receptor binding. To our knowledge, this report provides the first evidence implicating ROR1/2 as a viable therapeutic target in DIPG and establishes macrocyclic peptides as a promising modality for its pharmacological inhibition.
Funding Information
  • Japan Society for the Promotion of Science
  • Barncancerfonden (FT2023-0013)
  • Barncancerfonden (PR2022-0084)
  • Barncancerfonden (PR2023-0082)
  • Barncancerfonden (ST2015-0008)
  • Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement
  • JSPS Grant-in-Aid for Scientific Research (A) (22H00439)
  • JSPS Grant-in-Aid for Specially Promoted Research (JP20H05618)
  • Science for Life Laboratory, Sweden

This publication has 52 references indexed in Scilit: